BRIEF-FDA Grants Seastar Medical Breakthrough Device Designation For Its Scd Therapy For The Treatment Of Hyperinflammation In Adult Patients With Sepsis Or A Septic Condition

3

Oct 7 (Reuters) – SeaStar Medical Holding Corp: * FDA GRANTS SEASTAR MEDICAL BREAKTHROUGH DEVICE DESIGNATION FOR ITS SCD THERAPY FOR THE TREATMENT OF HYPERINFLAMMATION IN ADULT PATIENTS WITH SEPSIS OR

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)